TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03185338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active commuting to/from school
Description: Active transport to/from school on foot or by bike will be promoted

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Physical Education lessons
Description: Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Physical Education lessons
Description: Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active school recess
Description: Teachers will design games and activities and will encourage children for being active

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active school recess
Description: Teachers will design games and activities and will encourage children for being active

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep health promotion
Description: This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep health promotion
Description: This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School global intervention
Description: A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
Study: NCT03087578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupncture
Description: Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
Study: NCT01917318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During 8 weeks subjects will receive oral placebo
Study: NCT02791243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 0.25%
Description: Cutaneous solution of finasteride 0.25%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Finasteride 0.25%
Description: vehicle cutaneous solution of P-3074

Intervention type: DRUG
Group type: OTHER
Intervention: Negative Control
Description: 0.9% aqueous NaCl
Study: NCT01650402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive therapy to SBP 130 mm Hg
Description: Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive therapy to SBP 145 mm Hg
Description: Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
Study: NCT02002325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (alteplase)
Description: Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard treatment for acute stroke without intravenous alteplase.
Study: NCT00982384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease management
Description: Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best care
Description: Comprehensive care for COPD patients recommended in clinical guidelines
Study: NCT04259593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Study: NCT03087578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG [Myrbetriq]
Description: Patients will receive 50 mg of mirabegron daily for 6 weeks.
Study: NCT04698213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib Oral Tablet
Description: Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
Study: NCT00991380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALD
Description: A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Control
Study: NCT00463658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls Prevention
Description: Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
Study: NCT00401076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-001
Description: 0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
Study: NCT00863161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: capsule, oral, single dose
Study: NCT03114267

Intervention type: OTHER
Intervention: Comparison of the prevalences of the parvovirus genome
Description: Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature

Intervention type: OTHER
Intervention: Comparison of the prevalences of the parvovirus genome
Description: Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
Study: NCT01220661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotetan
Description: preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
Study: NCT00081250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03411369

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine, D-Ribose, B1 Vitamin, and B6 vitamin
Description: The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
Study: NCT00788853

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is given
Study: NCT04186832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear FitBit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: Wear pedometer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02146443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretched arm test
Description: Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretched arm test
Description: Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretched arm test
Description: Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
Study: NCT04381143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg Oral Tablet
Description: Aspirin 100 mg tablet daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo 1 pill daily
Study: NCT01020175

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral blood stem cell transplantation
Description: Patients received filgrastim-mobilized peripheral blood stem cell transplantation
Study: NCT02146443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress
Description: During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
Study: NCT01466153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
Study: NCT02051894

Intervention type: DRUG
Intervention: Dobutamine
Description: Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis.
Study: NCT00605410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium bromide
Description: 2 puffs (40 micrograms) 2 puffs (0micrograms)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo
Study: NCT01822691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
Study: NCT01413048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25mg
Description: Tablet, q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSCT101 12.5mg
Description: Tablet, q.d.
Study: NCT03177980

Intervention type: DRUG
Intervention: Fentanyl
Description: The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
Study: NCT01466153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
Study: NCT02099175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
Study: NCT03177980

Intervention type: DRUG
Intervention: Fentanyl and clonidine
Description: In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
Study: NCT01605591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the DLT bending to the right
Description: bending the bronchial lumen of DLT 60\~90 degrees in the same side with the tracheal lumen

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the DLT bending to the left
Description: bending the bronchial lumen of DLT 60\~90 degree opposed to the tracheal lumen
Study: NCT00733382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethazone
Description: injection form, 8 miligram, injected once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethazone
Description: injection form, 8 miligram, injected once
Study: NCT00745368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg tablets twice daily during duration of trial
Study: NCT04330976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity intervention
Description: Messages sent on nutrition and physical activity in pregnancy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Messages sent on general health during pregnancy
Study: NCT00361712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia
Description: Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
Study: NCT01919645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Training ( Strength + Aerobics)
Description: Strength training performed using workout devices and aerobic training performed using stationary bicycle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Combined Training ( Strength + Aerobics)
Description: Strength training performed using workout devices and aerobic training performed using stationary bicycle.
Study: NCT04052919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac dysfunction in adolescents with type 1 diabetes
Description: to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM.
Study: NCT02885142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local excision for early rectal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local excision for early rectal cancer
Study: NCT02135965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate
Study: NCT02891525

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50g glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25g fructose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 220mg acesulfame-K
Study: NCT02135965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 100mg
Description: Albuterol 4mg and Caffeine 100mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 4mg and Caffeine 200mg
Description: Albuterol 4mg and Caffeine 200mg on metabolic rate
Study: NCT01507090

Intervention type: DEVICE
Intervention: Mercy TAPE
Description: 2D Mercy TAPE and 3D Mercy TAPE
Study: NCT03654664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Description: Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Inj
Description: 720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
Study: NCT01739634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CASAD
Description: CASAD is provided in 500mg capsules.
Study: NCT02610920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iron-tracer guided axillary ultrasound and biopsy
Description: After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron tracer
Description: All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
Study: NCT03505814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)
Description: High flow and humidified oxygen support for new borns and young infants for post-extubation care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen therapy
Description: conventional oxygen support for new born and young infants in post-extubation care
Study: NCT01387425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: varenicline at a dose of 1 mg twice a day for 12 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet is made of lactose
Description: placebo at a dose of 1 mg twice for 12 week
Study: NCT01885702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: DC vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: DC vaccination
Study: NCT04686513

Intervention type: OTHER
Intervention: Observation
Description: observational study

Intervention type: OTHER
Intervention: Observation
Description: observational study
Study: NCT00604227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Exposure
Description: ascent to 4559 m within 24 h without prior acclimatization
Study: NCT01583257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout based on active video gaming
Description: A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program